SEC Form 4 · accession 0001797917-26-000007
Keros Therapeutics, Inc. · KROS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anne Prener
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 4:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001664710
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 1, 2026 | A | 13,786 | $0.00 | A | 13,786 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $10.88 | Jul 1, 2026 | A | 14,870 | A | — | Jun 30, 2036 | Common Stock | 14,870 | 14,870 | D |
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on August 15, 2026, subject to the Reporting Person's continuous service through each such vesting date.
- F2The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on October 1, 2026, subject to the Reporting Person's continuous service through each such vesting date.